Active Ingredient History
JX-594 is an oncolytic virus is designed to target and destroy cancer cells. It is also known as Pexa-Vec, INN pexastimogene devacirepvec) and was constructed in Dr. Edmund Lattime's lab at Thomas Jefferson University, tested in clinical trials on melanoma patients, and licensed and further developed by SillaJen. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Breast Neoplasms (Phase 1/Phase 2)
Carcinoma, Hepatocellular (Phase 3)
Carcinoma, Renal Cell (Phase 1)
Colorectal Neoplasms (Phase 2)
Liver Neoplasms (Phase 2)
Lung Neoplasms (Phase 1)
Lymphoma (Phase 1)
Melanoma (Phase 1/Phase 2)
Neoplasm Metastasis (Phase 1)
Neoplasms (Phase 2)
Neuroblastoma (Phase 1)
Ovarian Neoplasms (Phase 2)
Rhabdomyosarcoma (Phase 1)
Sarcoma (Phase 2)
Sarcoma, Ewing (Phase 1)
Squamous Cell Carcinoma of Head and Neck (Phase 1)
Wilms Tumor (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue